申请人:Janssen Pharmaceutica N.V.
公开号:US06521621B1
公开(公告)日:2003-02-18
This invention concerns the compounds of formula
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein n is 0, 1 or 2; m is 1 or 2, provided that if m is 2, then n is 1; p is 1 or 2; ═Q is ═O or ═NR3; X is a covalent bond or a bivalent radical of formula —O—, —S—, —NR3—; R1 is Ar1, Ar1C1-6alkyl or di(Ar1)C1-6alkyl, wherein each C1-6alkyl group is optionally substituted with hydroxy, C1-4alkyloxy, oxo or a ketalized oxo substituent; R2 is Ar2, Ar2C1-6alkyl, Het1 or Het1C1-6alkyl; R3 is hydrogen or C1-6alkyl; L is hydrogen; Ar3; C1-6alkyl; C1-6alkyl substituted with 1 or 2 substituents selected from hydroxy, C1-6alkyloxy, Ar3, Ar3C1-6alkyloxy and Het2; C3-6alkenyl; Ar3C3-6alkenyl; di(Ar3)C3-6alkenyl or a radical of formula (a-1), (a-2), (a-3), (a-4) or (a-5); Ar1, Ar2 and Ar3 are each phenyl or substituted phenyl; Het1 and Het2 are each monocyclic or a bicyclic heterocycles; as substance-P antagonists; their preparation, compositions containing them and their use as a medicine.
本发明涉及公式N-氧化物形式的化合物、药学上可接受的加成盐和其立体异构体形式,其中n为0、1或2;m为1或2,但如果m为2,则n为1;p为1或2;═Q为═O或═NR3;X为共价键或式为—O—、—S—、—NR3—的双价基团;R1为Ar1、Ar1C1-6烷基或二(Ar1)C1-6烷基,其中每个C1-6烷基基团可选地取代为羟基、C1-4烷氧基、氧代或缩醛基取代基;R2为Ar2、Ar2C1-6烷基、Het1或Het1C1-6烷基;R3为氢或C1-6烷基;L为氢;Ar3;C1-6烷基;C1-6烷基取代1或2个选自羟基、C1-6烷氧基、Ar3、Ar3C1-6烷氧基和Het2的取代基;C3-6烯基;Ar3C3-6烯基;二(Ar3)C3-6烯基或式为(a-1)、(a-2)、(a-3)、(a-4)或(a-5)的基团;Ar1、Ar2和Ar3分别为苯基或取代苯基;Het1和Het2分别为单环或双环杂环;作为物质P拮抗剂;它们的制备、含有它们的组合物以及它们作为药物的用途。